S&P 500
(0.36%) 5 118.49 points
Dow Jones
(0.30%) 38 353 points
Nasdaq
(0.38%) 15 988 points
Oil
(-1.10%) $82.93
Gas
(3.48%) $1.990
Gold
(0.01%) $2 347.40
Silver
(0.08%) $27.56
Platinum
(3.18%) $951.45
USD/EUR
(-0.04%) $0.934
USD/NOK
(-0.06%) $11.02
USD/GBP
(-0.30%) $0.798
USD/RUB
(1.84%) $93.56

リアルタイムの更新: KYORIN Holdings, Inc. [4569.T]

取引所: JPX セクター: Healthcare 産業: Drug Manufacturers—Specialty & Generic
最終更新日時26 4月 2024 @ 15:15

0.99% ¥ 1 828.00

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 15:15):

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug...

Stats
本日の出来高 84 900.00
平均出来高 69 440.00
時価総額 105.02B
EPS ¥0 ( 2024-02-05 )
次の収益日 ( ¥0 ) 2024-05-08
Last Dividend ¥32.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 24.63
ATR14 ¥1.224 (0.07%)

ボリューム 相関

長: 0.12 (neutral)
短: 0.91 (very strong)
Signal:(59.072) Expect same movement, but be aware

KYORIN Holdings, Inc. 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

KYORIN Holdings, Inc. 相関 - 通貨/商品

The country flag 0.74
( moderate )
The country flag 0.86
( strong )
The country flag -0.19
( neutral )
The country flag 0.86
( strong )
The country flag -0.21
( neutral )
The country flag -0.87
( strong negative )

KYORIN Holdings, Inc. 財務諸表

Annual 2022
収益: ¥113.27B
総利益: ¥50.17B (44.29 %)
EPS: ¥82.42
FY 2022
収益: ¥113.27B
総利益: ¥50.17B (44.29 %)
EPS: ¥82.42
FY 2022
収益: ¥105.53B
総利益: ¥49.44B (46.85 %)
EPS: ¥68.62
FY 2021
収益: ¥102.90B
総利益: ¥51.63B (50.17 %)
EPS: ¥106.99

Financial Reports:

No articles found.

KYORIN Holdings, Inc. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥20.00
(N/A)
¥0
(N/A)
¥32.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

KYORIN Holdings, Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.14%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥10.00 2006-09-26
Last Dividend ¥32.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 35 --
Total Paid Out ¥862.50 --
Avg. Dividend % Per Year 0.00% --
Score 3.6 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.48 --
Next Divdend (Est)
(2024-07-03)
¥0 Estimate 0.00 %
Dividend Stability
0.10 Very Bad
Dividend Score
3.60
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
8125.T Ex Dividend Knight 2024-02-28 Annually 0 0.00%
7463.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
6678.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
6023.T Ex Dividend Knight 2024-03-28 Annually 0 0.00%
4716.T Ex Dividend Junior 2023-05-30 Annually 0 0.00%
3946.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
3168.T Ex Dividend Junior 2023-08-30 Semi-Annually 0 0.00%
2150.T Ex Dividend Knight 2023-12-29 Annually 0 0.00%
9663.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
8624.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.03561.5009.2910.00[0 - 0.5]
returnOnAssetsTTM0.02381.2009.2110.00[0 - 0.3]
returnOnEquityTTM0.03391.500-0.735-1.102[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM2.530.8002.341.871[1 - 3]
quickRatioTTM1.3270.8006.905.52[0.8 - 2.5]
cashRatioTTM0.4021.5008.8810.00[0.2 - 2]
debtRatioTTM0.116-1.5008.06-10.00[0 - 0.6]
interestCoverageTTM75.141.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM146.462.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM146.462.0010.0010.00[0 - 20]
debtEquityRatioTTM0.164-1.5009.34-10.00[0 - 2.5]
grossProfitMarginTTM0.4291.0006.186.18[0.2 - 0.8]
operatingProfitMarginTTM0.04081.000-1.185-1.185[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4051.0008.868.86[0.2 - 2]
assetTurnoverTTM0.6700.8008.877.10[0.5 - 2]
Total Score10.62

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM24.651.0007.610[1 - 100]
returnOnEquityTTM0.03392.50-0.472-1.102[0.1 - 1.5]
freeCashFlowPerShareTTM146.462.0010.0010.00[0 - 30]
dividendYielPercentageTTM2.841.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM146.462.0010.0010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM1.2261.5005.160[0.5 - 2]
operatingCashFlowSalesRatioTTM0.07021.000-0.7450[0.1 - 0.5]
Total Score4.34

KYORIN Holdings, Inc.

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。